-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board

PUBT·06/15/2026 12:30:42
Listen to the news
Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board
  • Fate Therapeutics appointed Laura Hamill to its board on June 15, 2026.
  • Hamill previously served as EVP, Worldwide Commercial Operations at Gilead Sciences, overseeing about $22 billion in annual revenue.
  • She spent nearly two decades at Amgen, including as SVP, U.S. Commercial Operations, leading a business unit representing roughly 80% of company revenue.
  • Fate is positioning for later-stage development and an expected transition toward commercialization of its iPSC-derived cell therapy programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150830PRIMZONEFULLFEED9746499) on June 15, 2026, and is solely responsible for the information contained therein.